Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models.

The observed antitumor effect translated to a highly significant long-term survival benefit, with nine mice (75%) surviving until the end point ( Fig. 5B ).

also in 132,142 other papers